Cardax (Cardax) Change In Working Capital : $1.14 Mil (TTM As of Mar. 2021)

View and export this data going back to 2012. Start your Free Trial

What is Cardax Change In Working Capital?

Cardax's change in working capital for the quarter that ended in Mar. 2021 was $0.39 Mil.

Cardax's change in working capital for the fiscal year that ended in Dec. 2020 was $1.05 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Cardax Change In Working Capital Historical Data

The historical data trend for Cardax's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardax Change In Working Capital Chart

Cardax Annual Data

Trend

Mar12

Mar13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Change In Working Capital

Get a 7-Day Free Trial

0.27

-0.37

0.05

0.01

1.05

Cardax Quarterly Data
	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
Change In Working Capital	Get a 7-Day Free Trial															0.30	0.22	0.32	0.21	0.39

Cardax Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.14 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Cardax Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Cardax's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardax (Cardax) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardax Inc (OTCPK:CDXI) » Definitions » Change In Working Capital

Comparable Companies

IMUN BOM:506365 PPCB HSTC XCNQ:NSHS RSPI BOM:542910 BOM:539206 RBSH GNBT

Traded in Other Exchanges

N/A

Address

2800 Woodlawn Drive, Suite 129, Honolulu, HI, USA, 96822

Website

http://www.cardaxpharma.com

Cardax Inc is a life sciences company engaged in the development of marketing, and distribution of consumer health products in the United States. The firm's platform has applications in arthritis, metabolic syndrome, liver disease, and cardiovascular disease, as well as macular degeneration and prostate disease. It is focused on the development of astaxanthin technologies. The group's product ZanthoSyn is marketed as a novel astaxanthin dietary supplement. Astaxanthin is a clinically studied ingredient with a safe anti-inflammatory activity that supports joint health, cardiovascular health, metabolic health, and liver health. Geographically, it generates maximum revenue from the United States.

Executives

Paulson Capital Corp	10 percent owner	222 THIRD STREET, SUITE 2241, CAMBRIDGE MA 02142
Paulson Investment Company, Inc.	10 percent owner	5335 MEADOWS ROAD SUITE 465 LAKE OSWEGO OR 97035
Paulson Cardax Investments 1 Llc	10 percent owner	811 SW NAITO PKWY SUITE 300 PORTLAND OR 97204